At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven relapsed, refractory, or residual CD20+ non-Hodgkin lymphomas
- ✓Histologic types: small lymphocytic lymphoma, lymphoplasmacytoid, follicular (grades 1-3), extranodal marginal zone, nodal marginal zone, diffuse large cell, or transformed lymphoma
- ✓≤25% bone marrow involvement by lymphoma on bilateral bone marrow aspirate and biopsy
- ✓Bi-dimensionally measurable disease with ≥1 lesion ≥2 cm single diameter
- ✕Prior myeloablative therapies with autologous or allogeneic bone marrow/stem cell transplantation
- ✕Prior radioimmunotherapy (Y-90 Zevalin, I-131 anti-B1, Lym-1)
- ✕CNS lymphoma
- ✕Myelodysplastic syndrome or marrow chromosomal changes suggesting myelodysplasia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, and 5 other interventions for Adult Non-Hodgkin Lymphoma and 11 related conditions. Completed, enrolled 38 participants across 2 sites.
Detailed Summary
RATIONALE: Biological therapies, such as agatolimod sodium, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving agatolimod sodium together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of agatolimod sodium when given together with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well it works in treating patients with recurrent or refractory non-Hodgkin lymphoma.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative study
Undergo imaging scans
Given IV
Undergo imaging scans
Given IV